VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | PARACHUTE trial: ATG in HCST

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the PARACHUTE-trial (NTR4960), involving anti-thymocyte globulin (ATG) introduction into the conditioning regimen in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host-disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter